Tags

Type your tag names separated by a space and hit enter

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
J Viral Hepat 2003; 10(1):37-42JV

Abstract

Even with pegylated (PEG) interferons (IFN), therapy of chronic hepatitis C (genotype 1) remains unsatisfactory. The initial viral response to IFN identifies patients infected with IFN resistant viruses not responding to standard IFN/ribavirin therapy. The impact of primary IFN unresponsiveness for PEG-IFN-alpha-2a/ribavirin therapy is unknown. Viral load was measured in 22 chronic hepatitis C (genotype 1) patients before and 24 h after 9 MU IFN-alpha-2a (days 0 and 1), and before and during weekly 180 microg PEG-IFN-alpha-2a (days 7, 8, 11, 14 and 21) administration. Thereafter, ribavirin (800 mg/d) was added for 6 months. Virological responders continued treatment for a further 6 months. Twenty-eight patients treated with standard IFN/ribavirin therapy in a previous study using an analogous protocol served as historic controls. After 6 months 15 (68.2%) patients were (HCV-RNA) negative, eight of whom (36.4%) had a sustained response. The decrease in viral load 24 h after 9 MU IFN-alpha-2a was greater in virological responders (1.05 log [0.25-1.67]) than in nonresponders (NR) (0.34 [0.14-0.65]; P=0.003). In contrast, viral decline was not different between responders and NRs during the first 2 weeks on PEG-IFN-alpha-2a. All patients with an initial decline > 1.4 log became sustained responders. Five of 12 patients with a log change < 0.8 became end of treatment responders, two had a sustained response. Antiviral response to PEG-IFN-alpha-2a is different to that on standard IFN. In spite of a lower initial response PEG-IFN-alpha-2a/ribavirin combination therapy may overcome predicted IFN unresponsiveness.

Authors+Show Affiliations

Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Vienna, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12558910

Citation

Jessner, W, et al. "Early Viral Kinetics On Treatment With Pegylated Interferon-alpha-2a in Chronic Hepatitis C Virus Genotype 1 Infection." Journal of Viral Hepatitis, vol. 10, no. 1, 2003, pp. 37-42.
Jessner W, Stauber R, Hackl F, et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat. 2003;10(1):37-42.
Jessner, W., Stauber, R., Hackl, F., Datz, C., Watkins-Riedel, T., Hofer, H., ... Ferenci, P. (2003). Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. Journal of Viral Hepatitis, 10(1), pp. 37-42.
Jessner W, et al. Early Viral Kinetics On Treatment With Pegylated Interferon-alpha-2a in Chronic Hepatitis C Virus Genotype 1 Infection. J Viral Hepat. 2003;10(1):37-42. PubMed PMID: 12558910.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. AU - Jessner,W, AU - Stauber,R, AU - Hackl,F, AU - Datz,C, AU - Watkins-Riedel,T, AU - Hofer,H, AU - Gangl,A, AU - Kessler,H, AU - Ferenci,P, PY - 2003/2/1/pubmed PY - 2003/5/28/medline PY - 2003/2/1/entrez SP - 37 EP - 42 JF - Journal of viral hepatitis JO - J. Viral Hepat. VL - 10 IS - 1 N2 - Even with pegylated (PEG) interferons (IFN), therapy of chronic hepatitis C (genotype 1) remains unsatisfactory. The initial viral response to IFN identifies patients infected with IFN resistant viruses not responding to standard IFN/ribavirin therapy. The impact of primary IFN unresponsiveness for PEG-IFN-alpha-2a/ribavirin therapy is unknown. Viral load was measured in 22 chronic hepatitis C (genotype 1) patients before and 24 h after 9 MU IFN-alpha-2a (days 0 and 1), and before and during weekly 180 microg PEG-IFN-alpha-2a (days 7, 8, 11, 14 and 21) administration. Thereafter, ribavirin (800 mg/d) was added for 6 months. Virological responders continued treatment for a further 6 months. Twenty-eight patients treated with standard IFN/ribavirin therapy in a previous study using an analogous protocol served as historic controls. After 6 months 15 (68.2%) patients were (HCV-RNA) negative, eight of whom (36.4%) had a sustained response. The decrease in viral load 24 h after 9 MU IFN-alpha-2a was greater in virological responders (1.05 log [0.25-1.67]) than in nonresponders (NR) (0.34 [0.14-0.65]; P=0.003). In contrast, viral decline was not different between responders and NRs during the first 2 weeks on PEG-IFN-alpha-2a. All patients with an initial decline > 1.4 log became sustained responders. Five of 12 patients with a log change < 0.8 became end of treatment responders, two had a sustained response. Antiviral response to PEG-IFN-alpha-2a is different to that on standard IFN. In spite of a lower initial response PEG-IFN-alpha-2a/ribavirin combination therapy may overcome predicted IFN unresponsiveness. SN - 1352-0504 UR - https://www.unboundmedicine.com/medline/citation/12558910/Early_viral_kinetics_on_treatment_with_pegylated_interferon_alpha_2a_in_chronic_hepatitis_C_virus_genotype_1_infection_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1352-0504&amp;date=2003&amp;volume=10&amp;issue=1&amp;spage=37 DB - PRIME DP - Unbound Medicine ER -